Enrollment and outcomes were similar across racial and ethnic groups for children participating in therapeutic trials for Wilms tumor — the most common pediatric kidney cancer worldwide, according to a recent report in the Journal of the American College of Surgeons.

The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published Monday in JAMA Network Open authored by Wade Iams, MD, and colleagues indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.

Michael Topf, MD, Assistant Professor of Otolaryngology-Head and Neck Cancer Surgery at Vanderbilt wondered why computer-aided design (CAD) technology hadn’t made it into operating rooms as a visual aid for real-time consultations... So he decided to create it.

When the Vanderbilt Amyloid Multidisciplinary Program (VAMP) launched in 2011, it was the first center in Tennessee dedicated to patients with amyloidosis – a rare, systemic disorder that encompasses myriad presentations and organ dysfunctions. Since then, VAMP has paved the way to coordinated care as a major referral center in the southeastern United States, growing to include over a dozen collaborating specialists working to provide structured, multidisciplinary care to adults navigating an amyloidosis diagnosis.

Vanderbilt University School of Medicine Academy for Excellence in Clinical Medicine (AECM) has selected 25 new members.

Researchers find that ASTX727, a new oral combination therapy, can prolong survival in TP53-mutated MDS.

At the ripe age of 13, Jason Schwartz made a life-changing decision. Amid cancer treatment for Acute Lymphoblastic Leukemia (ALL), Schwartz was handed an incredible gift that would fuel his life’s work.

Research team refines method for diagnosis of indeterminant lung nodules using artificial intelligence and advanced learning.

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center's research programs.

Pediatric oncologists and cardiologists collaborate on reducing cardiotoxic effects of cancer treatment.

Multifaceted study connects early amplified oncogene MDM2 with outcomes and therapy responses.

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.

Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.

Oluwole’s patients often call him “Dr. O,” and he is one of the nation’s top CAR T experts. He is an author of a study published in The New England Journal of Medicine in 2017 that showed CAR T is an effective treatment for refractory large B-cell lymphoma.

Vanderbilt researcher P. Brent Ferrell, MD, is leading one of five projects selected by the 2022 Novartis Institutes for BioMedical Research Global Scholars Program.

A Vanderbilt study found that a molecular signature that predicts aggressive thyroid cancer could help guide treatment approaches for patients.

Vanderbilt investigators have discovered that vasopressin, which has long been thought to be produced only in the brain, is also produced in the kidney.

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC)

Vanderbilt University Medical Center scientists are launching a research platform called ELVIS that is devoted to molecular underpinnings of early-childhood determinants of health.